Ask AI
Case Challenge: NSCLC

CE / CME

Biomarker Testing in Patients With Solid Tumors: Interactive Case Challenge for NSCLC

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Released: June 16, 2026

Expiration: December 15, 2026

Activity

Progress
1 2
Course Completed

Patient History/Initial Presentation
A 68-year-old woman presents with a persistent dry cough and new back pain. Workup shows a large spinal metastasis, and a CT scan of chest/abdomen/pelvis reveals a large left upper lobe lung mass. She is diagnosed with stage IV lung cancer, pending confirmation of full metastatic extent and pathology as clinically appropriate.

Her social history is notable for approximately 2 pack-years of smoking during college, with cessation approximately 50 years ago. For practical purposes, she has minimal remote smoking exposure; however, broad biomarker testing is indicated for advanced lung adenocarcinoma regardless of smoking history. Bronchoscopy with biopsy of the left upper lobe mass confirms lung adenocarcinoma, and in-house PD-L1 immunohistochemistry testing shows PD-L1 expression of 10%. Reflex biomarker testing is initiated once adenocarcinoma is identified based on institutional protocols. When she presents to medical oncology, PD-L1 status is available, but the broader molecular/next-generation sequencing (NGS) report is still pending and expected within approximately 2-3 weeks.

Your patient has newly diagnosed metastatic lung adenocarcinoma with PD-L1 expression of 10% by immunohistochemistry, and broad-panel NGS is still pending. She is clinically stable, scared, and wants to start treatment immediately. 

What is the most appropriate information that you would communicate to her as the next step in her care and the reason supporting it?